Current Update of Pharmacogenomic in Drug Discovery and Development : A narrative review
Keywords:
drug discovery, drug development, pharmacogenomic, pharmacogenetic, personalized medicine
Abstract
Pharmacogenomics currently has an essential role in drug discovery and development. Research related to pharmacogenomics has increased rapidly since the human genome project was completed in the early 20th century, increasing awareness of the importance of personalized medicine, which is expected to be safer and more beneficial for human health. Therefore, this article aims to review recent developments regarding pharmacogenomics in drug discovery and development. In addition, this article will also discuss the challenges that still exist in the implementation of pharmacogenomics in drug development and clinical practice. It is hoped that these challenges can be overcome in the future with collaboration between researchers, practitioners, and the government so that precision and personalized therapy can be realized for each individual.
Keywords: drug discovery, drug development, pharmacogenetic, pharmacogenomic
References
1. Roden DM, McLeod HL, Relling M V, et al. Pharmacogenomics. Lancet (London, England). 2019;394(10197):521-532. doi:10.1016/S0140-6736(19)31276-0
2. Scott SA, Swen JJ. Pharmacogenomic determinants of interindividual drug response variability: From discovery to implementation. Genes (Basel). 2021;12(3):10-13. doi:10.3390/genes12030393
3. Mirsadeghi S, Larijani B. Personalized medicine: Pharmacogenomics and drug development. Acta Med Iran. 2017;55(3):150-165.
4. Sinha S, Vohora D. Drug Discovery and Development: An Overview. Elsevier Inc.; 2017. doi:10.1016/B978-0-12-802103-3.00002-X
5. Dugger SA, Platt A, Goldstein DB. Drug development in the era of precision medicine. Nat Rev Drug Discov. 2018;17(3):183-196. doi:10.1038/nrd.2017.226
6. Fulton CR, Swart M, De Luca T, et al. Pharmacogenetics and Practice: Tailoring Prescribing for Safety and Effectiveness. J Nurse Pract. 2018;14(10):697-704.e1. doi:10.1016/j.nurpra.2018.09.021
7. Surendiran A, Pradhan S, Adithan C. Role of pharmacogenomics in drug discovery and development. Indian J Pharmacol. 2008;40(4):137-143. doi:10.4103/0253-7613.43158
8. Dugger SA, Platt A, Goldstein DB, et al. HHS Public Access. 2018;17(3):183-196. doi:10.1038/nrd.2017.226.Drug
9. Spreafico R, Soriaga LB, Grosse J, Virgin HW, Telenti A. Advances in genomics for drug development. Genes (Basel). 2020;11(8):1-19. doi:10.3390/genes11080942
10. Sun W, Zheng W, Simeonov A. Drug discovery and development for rare genetic disorders. 2017;(May). doi:10.1002/ajmg.a.38326
11. Mohd A, Amar J Das. Current Trends in Drug Discovery: Target Identification To Clinical Development of the Drug. Int Res J Pharm. 2012;3(4):23-27.
12. Deore AB, Dhumane JR, Wagh R, Sonawane R. The Stages of Drug Discovery and Development Process. Asian J Pharm Res Dev. 2019;7(6):62-67. doi:10.22270/ajprd.v7i6.616
13. Gupta S, Jhawat V. Quality by design (QbD) approach of pharmacogenomics in drug designing and formulation development for optimization of drug delivery systems. J Control Release. 2017;245:15-26. doi:10.1016/j.jconrel.2016.11.018
14. A. O, T. J. A review on the role of pharmacogenomics in drug discovery and development. Int J Pharm Sci Res. 2016;7(9):3587-3595. doi:10.13040/IJPSR.0975-8232.7(9).3587-95
15. Kiriiri GK, Njogu PM, Mwangi AN. Exploring different approaches to improve the success of drug discovery and development projects: a review. Futur J Pharm Sci. 2020;6(1). doi:10.1186/s43094-020-00047-9
16. Gashaw I, Ellinghaus P, Sommer A, Asadullah K. What makes a good drug target? Drug Discov Today. 2011;16(23-24):1037-1043. doi:10.1016/j.drudis.2011.09.007
17. Lin X, Li X, Lin X. A review on applications of computational methods in drug screening and design. Molecules. 2020;25(6):1-17. doi:10.3390/molecules25061375
18. Pushpakom S, Iorio F, Eyers PA, et al. Drug repurposing: Progress, challenges and recommendations. Nat Rev Drug Discov. 2018;18(1):41-58. doi:10.1038/nrd.2018.168
19. Pulley JM, Shirey-Rice JK, Lavieri RR, et al. Accelerating Precision Drug Development and Drug Repurposing by Leveraging Human Genetics. Assay Drug Dev Technol. 2017;15(3):113-119. doi:10.1089/adt.2016.772
20. Russell LE, Zhou Y, Almousa AA, Sodhi JK, Nwabufo CK, Lauschke VM. Pharmacogenomics in the era of next generation sequencing–from byte to bedside. Drug Metab Rev. 2021;53(2):253-278. doi:10.1080/03602532.2021.1909613
21. Moyer AM, Caraballo PJ. The challenges of implementing pharmacogenomic testing in the clinic. Expert Rev Pharmacoeconomics Outcomes Res. 2017;17(6):567-577. doi:10.1080/14737167.2017.1385395
22. O’Shea J, Ledwidge M, Gallagher J, Keenan C, Ryan C. Pharmacogenetic interventions to improve outcomes in patients with multimorbidity or prescribed polypharmacy: a systematic review. Pharmacogenomics J. 2022;22(2):89-99. doi:10.1038/s41397-021-00260-6
23. Bienfait K, Chhibber A, Marshall JC, et al. Current challenges and opportunities for pharmacogenomics: perspective of the Industry Pharmacogenomics Working Group (I-PWG). Hum Genet. 2021;(0123456789). doi:10.1007/s00439-021-02282-3
24. Tarantino P, Trapani D, Morganti S, et al. Opportunities and challenges of implementing Pharmacogenomics in cancer drug development. Cancer Drug Resist. 2019;2(1):43-52. doi:10.20517/cdr.2018.22
25. Alomar M, Tawfiq AM, Hassan N, Palaian S. Post marketing surveillance of suspected adverse drug reactions through spontaneous reporting: current status, challenges and the future. Ther Adv drug Saf. 2020;11:2042098620938595. doi:10.1177/2042098620938595
26. Burt T, Dhillon S. Pharmacogenomics in early-phase clinical development. Pharmacogenomics. 2013;14(9):1085-1097. doi:10.2217/pgs.13.81
27. Agúndez JAG, Gómez-Tabales J, Ruano F, García-Martin E. The potential role of pharmacogenomics and biotransformation in hypersensitivity reactions to paracetamol. Curr Opin Allergy Clin Immunol. 2018;18(4):302-309. doi:10.1097/ACI.0000000000000452
28. Macías Y, García-Menaya JM, Martí M, et al. Lack of Major Involvement of Common CYP2C Gene Polymorphisms in the Risk of Developing Cross-Hypersensitivity to NSAIDs. Front Pharmacol. 2021;12(September). doi:10.3389/fphar.2021.648262
29. Van Der Horst J, Manville RW, Hayes K, Thomsen MB, Abbott GW, Jepps TA. Acetaminophen (Paracetamol) Metabolites Induce Vasodilation and Hypotension by Activating Kv7 Potassium Channels Directly and Indirectly. Arterioscler Thromb Vasc Biol. 2020;(May):1207-1219. doi:10.1161/ATVBAHA.120.313997
30. Shekhani R, Steinacher L, Swen JJ, Ingelman-Sundberg M. Evaluation of Current Regulation and Guidelines of Pharmacogenomic Drug Labels: Opportunities for Improvements. Clin Pharmacol Ther. 2020;107(5):1240-1255. doi:10.1002/cpt.1720
31. Dickmann LJ, Ware JA. Pharmacogenomics in the age of personalized medicine. Drug Discov Today Technol. 2016;21-22:11-16. doi:10.1016/j.ddtec.2016.11.003
32. Government UK. Genomics Beyond Health - full report. Published 2022. Accessed May 28, 2022. https://www.gov.uk/government/publications/genomics-beyond-health/genomics-beyond-health-full-report-accessible-webpage
33. Prudent J, Lopez E, Dorshorst D, Cox HC, Bodurtha JN. Demographic and socioeconomic trends in DNA banking utilization in the USA. J Community Genet. 2021;12(4):593-602. doi:10.1007/s12687-021-00533-4
2. Scott SA, Swen JJ. Pharmacogenomic determinants of interindividual drug response variability: From discovery to implementation. Genes (Basel). 2021;12(3):10-13. doi:10.3390/genes12030393
3. Mirsadeghi S, Larijani B. Personalized medicine: Pharmacogenomics and drug development. Acta Med Iran. 2017;55(3):150-165.
4. Sinha S, Vohora D. Drug Discovery and Development: An Overview. Elsevier Inc.; 2017. doi:10.1016/B978-0-12-802103-3.00002-X
5. Dugger SA, Platt A, Goldstein DB. Drug development in the era of precision medicine. Nat Rev Drug Discov. 2018;17(3):183-196. doi:10.1038/nrd.2017.226
6. Fulton CR, Swart M, De Luca T, et al. Pharmacogenetics and Practice: Tailoring Prescribing for Safety and Effectiveness. J Nurse Pract. 2018;14(10):697-704.e1. doi:10.1016/j.nurpra.2018.09.021
7. Surendiran A, Pradhan S, Adithan C. Role of pharmacogenomics in drug discovery and development. Indian J Pharmacol. 2008;40(4):137-143. doi:10.4103/0253-7613.43158
8. Dugger SA, Platt A, Goldstein DB, et al. HHS Public Access. 2018;17(3):183-196. doi:10.1038/nrd.2017.226.Drug
9. Spreafico R, Soriaga LB, Grosse J, Virgin HW, Telenti A. Advances in genomics for drug development. Genes (Basel). 2020;11(8):1-19. doi:10.3390/genes11080942
10. Sun W, Zheng W, Simeonov A. Drug discovery and development for rare genetic disorders. 2017;(May). doi:10.1002/ajmg.a.38326
11. Mohd A, Amar J Das. Current Trends in Drug Discovery: Target Identification To Clinical Development of the Drug. Int Res J Pharm. 2012;3(4):23-27.
12. Deore AB, Dhumane JR, Wagh R, Sonawane R. The Stages of Drug Discovery and Development Process. Asian J Pharm Res Dev. 2019;7(6):62-67. doi:10.22270/ajprd.v7i6.616
13. Gupta S, Jhawat V. Quality by design (QbD) approach of pharmacogenomics in drug designing and formulation development for optimization of drug delivery systems. J Control Release. 2017;245:15-26. doi:10.1016/j.jconrel.2016.11.018
14. A. O, T. J. A review on the role of pharmacogenomics in drug discovery and development. Int J Pharm Sci Res. 2016;7(9):3587-3595. doi:10.13040/IJPSR.0975-8232.7(9).3587-95
15. Kiriiri GK, Njogu PM, Mwangi AN. Exploring different approaches to improve the success of drug discovery and development projects: a review. Futur J Pharm Sci. 2020;6(1). doi:10.1186/s43094-020-00047-9
16. Gashaw I, Ellinghaus P, Sommer A, Asadullah K. What makes a good drug target? Drug Discov Today. 2011;16(23-24):1037-1043. doi:10.1016/j.drudis.2011.09.007
17. Lin X, Li X, Lin X. A review on applications of computational methods in drug screening and design. Molecules. 2020;25(6):1-17. doi:10.3390/molecules25061375
18. Pushpakom S, Iorio F, Eyers PA, et al. Drug repurposing: Progress, challenges and recommendations. Nat Rev Drug Discov. 2018;18(1):41-58. doi:10.1038/nrd.2018.168
19. Pulley JM, Shirey-Rice JK, Lavieri RR, et al. Accelerating Precision Drug Development and Drug Repurposing by Leveraging Human Genetics. Assay Drug Dev Technol. 2017;15(3):113-119. doi:10.1089/adt.2016.772
20. Russell LE, Zhou Y, Almousa AA, Sodhi JK, Nwabufo CK, Lauschke VM. Pharmacogenomics in the era of next generation sequencing–from byte to bedside. Drug Metab Rev. 2021;53(2):253-278. doi:10.1080/03602532.2021.1909613
21. Moyer AM, Caraballo PJ. The challenges of implementing pharmacogenomic testing in the clinic. Expert Rev Pharmacoeconomics Outcomes Res. 2017;17(6):567-577. doi:10.1080/14737167.2017.1385395
22. O’Shea J, Ledwidge M, Gallagher J, Keenan C, Ryan C. Pharmacogenetic interventions to improve outcomes in patients with multimorbidity or prescribed polypharmacy: a systematic review. Pharmacogenomics J. 2022;22(2):89-99. doi:10.1038/s41397-021-00260-6
23. Bienfait K, Chhibber A, Marshall JC, et al. Current challenges and opportunities for pharmacogenomics: perspective of the Industry Pharmacogenomics Working Group (I-PWG). Hum Genet. 2021;(0123456789). doi:10.1007/s00439-021-02282-3
24. Tarantino P, Trapani D, Morganti S, et al. Opportunities and challenges of implementing Pharmacogenomics in cancer drug development. Cancer Drug Resist. 2019;2(1):43-52. doi:10.20517/cdr.2018.22
25. Alomar M, Tawfiq AM, Hassan N, Palaian S. Post marketing surveillance of suspected adverse drug reactions through spontaneous reporting: current status, challenges and the future. Ther Adv drug Saf. 2020;11:2042098620938595. doi:10.1177/2042098620938595
26. Burt T, Dhillon S. Pharmacogenomics in early-phase clinical development. Pharmacogenomics. 2013;14(9):1085-1097. doi:10.2217/pgs.13.81
27. Agúndez JAG, Gómez-Tabales J, Ruano F, García-Martin E. The potential role of pharmacogenomics and biotransformation in hypersensitivity reactions to paracetamol. Curr Opin Allergy Clin Immunol. 2018;18(4):302-309. doi:10.1097/ACI.0000000000000452
28. Macías Y, García-Menaya JM, Martí M, et al. Lack of Major Involvement of Common CYP2C Gene Polymorphisms in the Risk of Developing Cross-Hypersensitivity to NSAIDs. Front Pharmacol. 2021;12(September). doi:10.3389/fphar.2021.648262
29. Van Der Horst J, Manville RW, Hayes K, Thomsen MB, Abbott GW, Jepps TA. Acetaminophen (Paracetamol) Metabolites Induce Vasodilation and Hypotension by Activating Kv7 Potassium Channels Directly and Indirectly. Arterioscler Thromb Vasc Biol. 2020;(May):1207-1219. doi:10.1161/ATVBAHA.120.313997
30. Shekhani R, Steinacher L, Swen JJ, Ingelman-Sundberg M. Evaluation of Current Regulation and Guidelines of Pharmacogenomic Drug Labels: Opportunities for Improvements. Clin Pharmacol Ther. 2020;107(5):1240-1255. doi:10.1002/cpt.1720
31. Dickmann LJ, Ware JA. Pharmacogenomics in the age of personalized medicine. Drug Discov Today Technol. 2016;21-22:11-16. doi:10.1016/j.ddtec.2016.11.003
32. Government UK. Genomics Beyond Health - full report. Published 2022. Accessed May 28, 2022. https://www.gov.uk/government/publications/genomics-beyond-health/genomics-beyond-health-full-report-accessible-webpage
33. Prudent J, Lopez E, Dorshorst D, Cox HC, Bodurtha JN. Demographic and socioeconomic trends in DNA banking utilization in the USA. J Community Genet. 2021;12(4):593-602. doi:10.1007/s12687-021-00533-4
